lefitolimod   Click here for help

GtoPdb Ligand ID: 14710

Synonyms: MGN-1703 | MGN1703
Immunopharmacology Ligand
Compound class: Nucleic acid
Comment: Lefitolimod (MGN-1703) is a CpG oligonucleotide that was intended to act as a Toll-like receptor 9 (TLR9) agonist to stimulate innate and adaptive immunity. It behaves as a double-stem loop immunomodulator, with CpG motifs at both ends.
Click here for help
References
1. Gunst JD, Højen JF, Pahus MH, Rosás-Umbert M, Stiksrud B, McMahon JH, Denton PW, Nielsen H, Johansen IS, Benfield T et al.. (2023)
Impact of a TLR9 agonist and broadly neutralizing antibodies on HIV-1 persistence: the randomized phase 2a TITAN trial.
Nat Med, 29 (10): 2547-2558. [PMID:37696935]
2. Kapp K, Volz B, Oswald D, Wittig B, Baumann M, Schmidt M. (2019)
Beneficial modulation of the tumor microenvironment and generation of anti-tumor responses by TLR9 agonist lefitolimod alone and in combination with checkpoint inhibitors.
Oncoimmunology, 8 (12): e1659096. [PMID:31741757]
3. Krarup AR, Abdel-Mohsen M, Schleimann MH, Vibholm L, Engen PA, Dige A, Wittig B, Schmidt M, Green SJ, Naqib A et al.. (2018)
The TLR9 agonist MGN1703 triggers a potent type I interferon response in the sigmoid colon.
Mucosal Immunol, 11 (2): 449-461. [PMID:28766555]
4. Nardo M, Gouda MA, Reilley MJ, Biter AB, Lim J, Bean SA, Nguyen LM, Bhosale PR, Ager CR, Couillault CA et al.. (2025)
Lefitolimod in Combination with Ipilimumab in Patients with Advanced Solid Tumors: A Phase I Trial.
J Immunother Precis Oncol, 8 (2): 89-98. [PMID:39959251]
5. Reilley MJ, Morrow B, Ager CR, Liu A, Hong DS, Curran MA. (2019)
TLR9 activation cooperates with T cell checkpoint blockade to regress poorly immunogenic melanoma.
J Immunother Cancer, 7 (1): 323. [PMID:31771649]
6. Thomas M, Ponce-Aix S, Navarro A, Riera-Knorrenschild J, Schmidt M, Wiegert E, Kapp K, Wittig B, Mauri C, Dómine Gómez M et al.. (2018)
Immunotherapeutic maintenance treatment with toll-like receptor 9 agonist lefitolimod in patients with extensive-stage small-cell lung cancer: results from the exploratory, controlled, randomized, international phase II IMPULSE study.
Ann Oncol, 29 (10): 2076-2084. [PMID:30137193]
7. Vibholm LK, Konrad CV, Schleimann MH, Frattari G, Winckelmann A, Klastrup V, Jensen NM, Jensen SS, Schmidt M, Wittig B et al.. (2019)
Effects of 24-week Toll-like receptor 9 agonist treatment in HIV type 1+ individuals.
AIDS, 33 (8): 1315-1325. [PMID:30932955]
8. Wittig B, Schmidt M, Scheithauer W, Schmoll HJ. (2015)
MGN1703, an immunomodulator and toll-like receptor 9 (TLR-9) agonist: from bench to bedside.
Crit Rev Oncol Hematol, 94 (1): 31-44. [PMID:25577571]